LSBCFPharmaceutical PreparationsIFRS · EUR

LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Co., Ltd. is a biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics. Its work centers on infectious diseases and cancer, with operations based in Beijing, China and a corporate listing structure that includes reporting in the United States.

Kysy yhtiöstä
Liikevaihto615milj. EUR
+7,2 %v/v
Liikevoitto (EBIT)−86,3milj. EUR
+80,6 %v/v
EBIT-marginaali−14,0%
+63,7 %-yks.v/v
Nettotulos−100,0milj. EUR
+76,9 %v/v
Vapaa kassavirta−134milj. EUR
+60,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−500−2500250500750milj. EUR2021: 257 milj. EUR2021: EBIT −126 milj. EUR20212022: 503 milj. EUR2022: EBIT −119 milj. EUR20222023: 687 milj. EUR2023: EBIT −139 milj. EUR20232024: 573 milj. EUR2024: EBIT −446 milj. EUR20242025: 615 milj. EUR2025: EBIT −86 milj. EUR2025615−86
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Vaccines45 %

Preventive vaccine candidates and related vaccine products for infectious diseases.

Therapeutic biologics35 %

Biologic therapies developed for infectious diseases and oncology indications.

Platform technology10 %

PIKA® immunomodulating technology used to support vaccine and biologics development.

Research and development services10 %

Preclinical and clinical development activities for internal and partnered programs.

Asiakkaat

LakeShore Biopharma sells into public health, healthcare, and life-science channels that need vaccines or biologics for infectious disease prevention and treatment. Its products are ultimately used by patients, but procurement and adoption are driven by governments, healthcare systems, distributors, and clinical partners that evaluate efficacy, safety, and manufacturing capability. The business also depends on research collaborators and regulators because development-stage biologics require extensive clinical and approval pathways.

Public health and government buyers

Buy vaccines for disease prevention programs and outbreak response, where procurement depends on public health needs and regulatory approval.

Hospitals and healthcare providers

Use therapeutic biologics and related products in treatment settings, typically based on clinical utility and reimbursement access.

Distribution partners

Purchase or distribute products to extend market reach and support commercialization in multiple geographies.

Research and clinical collaborators

Work with the company on development programs and platform technology, helping advance vaccine and biologics candidates.

Strategia

LakeShore Biopharma’s strategy appears centered on advancing vaccine and biologics programs built on its PIKA® immunomodulating platform. The reported merger activity suggests a major ownership or capital-structure transition, which can affect how the company funds development, commercializes products, and structures long-term growth. Its competitive position depends on moving programs through clinical development and into manufacturable, distributable products for infectious disease and oncology markets.

Advance core vaccine and biologics pipelineKeskipitkä aikaväli

Clinical and regulatory progress is essential for turning platform science into approved products.

Leverage PIKA® technology platformKeskipitkä aikaväli

A proprietary platform can improve differentiation and support multiple product candidates.

Strengthen corporate and funding structureLyhyt aikaväli

Biopharma development requires capital and may benefit from a structure that supports financing and strategic flexibility.

Maantiede

The company is headquartered in Beijing, China but reports as a foreign private issuer in the United States and has securities traded in U.S. over-the-counter markets. Its business is described as global, implying cross-border development, manufacturing, and commercialization exposure across multiple markets rather than a single-country operation.

Riskit

The company faces development-stage biopharma risks, including clinical trial failure, regulatory delays, and commercialization uncertainty for vaccine and biologic candidates. It is also exposed to cross-border operating and financing risk because its core operations are in China while its securities reporting and investor base are linked to the United States.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory approval delays2Manufacturing and quality control3China-U.S. cross-border exposure4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea

    Biopharmaceutical candidates may not meet efficacy or safety endpoints in trials.

    Kohdistuu: Vaccine and therapeutic biologic pipeline

  2. Regulatory approval delaysVaikutus: KorkeaTodennäköisyys: Korkea

    Vaccines and biologics require extensive review by health authorities before commercialization.

    Kohdistuu: Infectious disease and oncology products

  3. Manufacturing and quality controlVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Biologics are sensitive to process consistency, yield, and compliance requirements.

    Kohdistuu: R&D and manufacturing operations

  4. China-U.S. cross-border exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Operations in China and reporting/access to U.S. capital markets can create legal, governance, and market-access complexity.

    Kohdistuu: Corporate structure and listing

Kirjanpito

Harkinnanvaraiset erät
Research and development expenses

Biopharma companies typically expense most development costs as incurred, which makes reported results highly sensitive to pipeline activity.

Vaikutus: Affects operating expense profile and comparability across periods

Revenue recognition from collaborations

Any licensing, milestone, or partner funding arrangements require judgment on timing and performance obligations.

Vaikutus: Can shift revenue between periods

Intangible asset impairment

Development-stage assets can lose value if trials fail, timelines slip, or commercialization prospects weaken.

Vaikutus: May create large non-cash charges

Lease accounting

Laboratory, office, and manufacturing facilities create right-of-use assets and lease liabilities.

Vaikutus: Affects balance sheet leverage and expense profile

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lakefront Biotherapeutics NV

LKFT · Pharmaceutical Preparations

Connect Biopharma Holdings Ltd

CNTB · Pharmaceutical Preparations

Sunshine Biopharma Inc.

SBFMW · Pharmaceutical Preparations

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

Cue Biopharma, Inc.

CUE · Pharmaceutical Preparations

Arbutus Biopharma Corp

ABUS · Pharmaceutical Preparations

Päivitetty: 28.9.2026